Injection methods and usage guidelines for bimekizumab

Bimekizumab (Bimekizumab) is a new type of humanized monoclonal IgG1 antibody with a dual mechanism of action. It mainly regulates immune responses by inhibiting two cytokines, IL-17A and IL-17F. This drug is widely used to treat a variety of immune-mediated diseases, especially in the treatment of skin and joint-related diseases, showing clinical effects. Bichizumab's innovative mechanism of action makes it therapeutically important in multiple indications.

1. Bicizumab, as an inhibitor ofIL-17A and IL-17F, is mainly used to treat the following indications:1. Moderate to severe plaque psoriasis: Bicizumab is suitable for adult patients with moderate to severe plaque psoriasis, especially those who may benefit from systemic therapy or ultraviolet (phototherapy) treatment. It significantly improves skin lesions by inhibiting inflammatory responses, reducing inflammation and itching, and promoting skin recovery.

2. Psoriatic arthritis: Bicizumab has also shown significant efficacy in adults with active psoriatic arthritis, especially those with significant joint inflammation. The medication helps patients regain movement by reducing inflammation in the joints, relieving pain and stiffness.

3. Non-radiographic axial spondyloarthritis: For adults with active non-radiographic axial spondyloarthritis, bichizumab can also effectively reduce inflammation of the spine and hip, relieve related symptoms, and improve the patient's flexibility and quality of life.

4. Ankylosing spondylitis: Bicizumab can effectively treat adult patients with active ankylosing spondylitis, reducing inflammation of the spine and joints, alleviating symptoms, and improving the patient's motor function.

5. Moderate to severe hidradenitis suppurativa: Hidradenitis suppurativa is a serious skin disease that is often accompanied by severe pain and recurring skin abscesses. The use of bicizumab in such patients can significantly reduce inflammation, reduce skin damage and symptoms, and improve the patient's quality of life.

2. Usage and dosage: Bicizumab is administered by subcutaneous injection. The specific dosage and dosage regimen vary according to the patient's indications and disease severity. The following are recommended dosages and injection regimens for different indications:

1. Plaque psoriasis:For adult patients with moderate to severe plaque psoriasis, the recommended initial dose is320 mg. Subcutaneous injections are given at weeks 0, 4, 8, 12 and 16, and every 8 weeks thereafter. For patients weighing more than 120 kg, injections of 320 mg every 4 weeks may be considered after week 16 to ensure optimal treatment results.

2. Psoriatic arthritis: For patients with psoriatic arthritis, the recommended dose is 160 mg subcutaneously every 4 weeks. If patients also have moderate to severe plaque psoriasis, use the same dosing schedule of 320 mg every 8 weeks.

3. Non-radiological axial spondylitis: For adults with nonradiographic axial spondylitis, the recommended dose is 160 mg subcutaneously every 4 weeks.

4. Ankylosing spondylitis: For patients with ankylosing spondylitis, the recommended dose is 160 mg subcutaneously every 4 weeks.

5. Hidradenitis suppurativa: For patients with moderate to severe hidradenitis suppurativa, the initial dose is 320 mg, administered subcutaneously at weeks 0, 2, 4, 6, 8, 10, 12, 14 and 16 weeks, and then every 4 weeks.

As a new type of immunotherapy drug, bichizumab has a wide range of indications and can effectively treat immune system-related diseases such as psoriasis, arthritis, and spondylitis. Its unique dual mechanism of action occupies an important position in related therapeutic fields.

Keyword tags: Bimekizumab, drug information, indications, usage and dosage, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, immunotherapy

Reference materials:https://www.ucbsavings.com/sites/default/files/2025-01/Bimzelx%20_FAQ_011525.pdf